Sevikar HCT (olmesartan medoxomil, amlodipine besylate plus hydrochlorothiazide) from Daiichi Sankyo Europe, the first three-in-one pill to treat Hypertension, has...
The US patent on Diovan (valsartan) and the combination product Diovan HCT (valsartan plus the diuretic hydrochlorothiazide) from Novartis has...
ANI Pharmaceuticals, Inc. announced that it has acquired the NDAs and U.S. rights to market Atacand, Atacand HCT, Arimidex, and...
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Chimerix announced the presentation of final data from the AdVise trial of brincidofovir for the treatment of adenovirus (AdV) infection...
Chimerix announced that its Phase III SUPPRESS trial of brincidofovir in patients undergoing haematopoietic cell transplantation (HCT) did not achieve...
Merck Inc., announced the presentation of findings from a systematic literature review and meta-analysis of data from real-world observational studies of Prevymis (letermovir) for primary prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) who were CMV-seropositive.
Novartis announced that the CHMP has concluded the risk-benefit review of Rasilez (aliskiren) and combination products containing aliskiren and confirmed...
Atara Biotherapeutics announced that the Marketing Authorization Application (MAA) for tab-cel (tabelecleucel) has been fully validated by the European Medicines Agency (EMA).
